vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v16i1.1690vsp-1726Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWОбзор международных регистров пациентов с системным ювенильным идиопатическим артритомReview of International Registers of Patients with Systemic Juvenile Idiopathic Arthritishttps://orcid.org/0000-0002-3874-4721АлексееваЕ. И.AlekseevaEkaterina I.

чл.-корр. РАН, профессор, заведующая ревматологическим отделением ННПЦЗД, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

alekatya@yandex.ruЛомакинаО. Л.LomakinaOlga L.ВалиеваС. И.ValievaSaniya I.БзароваТ. М.BzarovaTatiana M.Национальный научно-практический центр здоровья детей, Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияNational Scientific and Practical Center of Children’s Health, Sechenov First Moscow State Medical UniversityRussian FederationНациональный научно-практический центр здоровья детейРоссияNational Scientific and Practical Center of Children’s HealthRussian FederationНациональный научно-практический центр здоровья детей, Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияNational Scientific and Practical Center of Children’s Health, Pirogov Russian National Research Medical UniversityRussian Federation2017060420171611823Copyright © Алексеева Е.И., Ломакина О.Л., Валиева С.И., Бзарова Т.М., 20172017Алексеева Е.И., Ломакина О.Л., Валиева С.И., Бзарова Т.М.Alekseeva E.I., Lomakina O.L., Valieva S.I., Bzarova T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1726

В статье представлен международный опыт мониторинга пациентов с ювенильным идиопатическим артритом. Основ ная цель большинства существующих международных регистров детей с ювенильным идиопатическим артритом — это оценка различных аспектов эффективности и безопасности генно-инженерных биологических препаратовв сравнении с метотрексатом. Результатов анализа эффективности регистров как инструмента многолетнего мониторинга заболевания и медицинской помощи детям с системным ювенильным идиопатическим артритом в доступной литературе мы не встретили.

The article describes the international experience in monitoring of patients with juvenile idiopathic arthritis. The main goal of most existing international registers of children with juvenile idiopathic arthritis is to evaluate various aspects of the effectiveness and safetyof genetic engineering biological drugs in comparison with methotrexate. No results from the analysis of the effectiveness of registers as a tool for long-term monitoring of the disease and medical care for children with systemic juvenile idiopathic arthritis have beenfound in the available literature.

детисистемный ювенильный идиопатический артритрегистрchildrensystemic juvenile idiopathic arthritisregisterСпонсор регистра сЮИА — компания «Рош», официальное юридическое лицо — ЗАО «Рош-Москва»ReferencesБаранов А.А., Алексеева Е.И. Ревматические болезни у детей.Клинические рекомендации для педиатра. — М: ПедиатрЪ; 2016. — 144 с. [Baranov AA, Alexeeva EI. Revmaticheskie bolezni u detei. Klinicheskie rekomendatsii dlya pediatra. Moscow: Pediatr”; 2016. 144 p. (In Russ).]Баранов А.А., Алексеева Е.И. Ревматические болезни у детей.Клинические рекомендации для педиатра. — М: ПедиатрЪ; 2016. — 144 с. [Baranov AA, Alexeeva EI. Revmaticheskie bolezni u detei. Klinicheskie rekomendatsii dlya pediatra. Moscow: Pediatr”; 2016. 144 p. (In Russ).]Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.Berntson L, Andersson Gare B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30(10):2275–2282.Berntson L, Andersson Gare B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30(10):2275–2282.Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33(7): 1377–1381.Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33(7): 1377–1381.Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75(9):1654–1660. doi: 10.1136/annrheumdis-2015-207818.Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75(9):1654–1660. doi: 10.1136/annrheumdis-2015-207818.Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 7th ed. Philadelphia: WB Saunders; 2016. p. 205–216.Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 7th ed. Philadelphia: WB Saunders; 2016. p. 205–216.Детская ревматология. Атлас. 2-е изд., перераб. и доп. / Под ред. Баранова А.А., Алексеевой Е.И. — М.: ПедиатрЪ; 2015. — С. 66–69. [Baranov AA, Alexeeva EI, editors. Detskaya revmatologiya. Atlas. 2nd ed. Moscow: Pediatr”; 2015. p. 66–69. (In Russ).]Детская ревматология. Атлас. 2-е изд., перераб. и доп. / Под ред. Баранова А.А., Алексеевой Е.И. — М.: ПедиатрЪ; 2015. — С. 66–69. [Baranov AA, Alexeeva EI, editors. Detskaya revmatologiya. Atlas. 2nd ed. Moscow: Pediatr”; 2015. p. 66–69. (In Russ).]Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей // Качество жизни. Медицина. — 2008. — №1 — С. 14–20. [Alexeeva EI. Rheumatic diseases and their influence on quality of life of children and their families. Kachestvo zhizni. Meditsina. 2008;(1):14–17. (In Russ).]Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей // Качество жизни. Медицина. — 2008. — №1 — С. 14–20. [Alexeeva EI. Rheumatic diseases and their influence on quality of life of children and their families. Kachestvo zhizni. Meditsina. 2008;(1):14–17. (In Russ).]Alexeeva EI, Baranov AA, Valieva SI, et al. Retrospective analysis of efficacy and safety of tocilizumab treatment in patients with severe systemic-onset juvenile idiopathic arthritis followed for 12 months. ISRN Immunology. 2013;2013:548312. doi: 10.1155/2013/548312.Alexeeva EI, Baranov AA, Valieva SI, et al. Retrospective analysis of efficacy and safety of tocilizumab treatment in patients with severe systemic-onset juvenile idiopathic arthritis followed for 12 months. ISRN Immunology. 2013;2013:548312. doi: 10.1155/2013/548312.Алексеева Е.И. Денисова Р.В. Канакинумаб в лечении ревматических болезней у детей // Вопросы современной педиатрии. — 2014. — Т. 13. — № 6 — С. 9–14. [Alexeeva EI, Denisova RV. Canakinumab in the treatment of rheumatic diseases in children. Current pediatrics. 2014;13(6):9–14. (In Russ).] doi: 10.15690/vsp.v13i6.1195.Алексеева Е.И. Денисова Р.В. Канакинумаб в лечении ревматических болезней у детей // Вопросы современной педиатрии. — 2014. — Т. 13. — № 6 — С. 9–14. [Alexeeva EI, Denisova RV. Canakinumab in the treatment of rheumatic diseases in children. Current pediatrics. 2014;13(6):9–14. (In Russ).] doi: 10.15690/vsp.v13i6.1195.Horneff G, Foeldvari I, Minden K, et al. [10 years experience in the German JIA. Etanercept Registry — lessons from changing patient populations. (In German).] Arthritis Rheum (Munich). 2011; 31(5):334–342.Horneff G, Foeldvari I, Minden K, et al. [10 years experience in the German JIA. Etanercept Registry — lessons from changing patient populations. (In German).] Arthritis Rheum (Munich). 2011; 31(5):334–342.Horneff G, Minden K, Foeldvari I, et al. [Current news from the BIKER register. (In German).] Z Rheumatol. 2014;73(10):897– 906. doi: 10.1007/s00393-014-1397-9.Horneff G, Schmeling H,Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12): 1638–1644. doi: 10.1136/ard.2003.014886.Horneff G, Minden K, Foeldvari I, et al. [Current news from the BIKER register. (In German).] Z Rheumatol. 2014;73(10):897– 906. doi: 10.1007/s00393-014-1397-9.Horneff G, Schmeling H,Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12): 1638–1644. doi: 10.1136/ard.2003.014886.Minden K, Klotsche J, Niewerth M, et al. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis. (In German).] Z Rheumatol. 2013;72(4):339–346. doi: 10.1007/s00393-012-1063-z.Minden K, Klotsche J, Niewerth M, et al. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis. (In German).] Z Rheumatol. 2013;72(4):339–346. doi: 10.1007/s00393-012-1063-z.Cassell S, Tutuncu Z, Kremer J, et al. Psoriatic arthritis (PsA) patients (pts) have different rates of adverse events (AE) than rheumatoid arthritis (PA) pts when treated with tumor necrosis factor inhibitors: analysis from the CORRONA database. American College of Rheumatology 69th Annual Scientific Meeting; 2005 Nov 12–17; San Diego, USA.Cassell S, Tutuncu Z, Kremer J, et al. Psoriatic arthritis (PsA) patients (pts) have different rates of adverse events (AE) than rheumatoid arthritis (PA) pts when treated with tumor necrosis factor inhibitors: analysis from the CORRONA database. American College of Rheumatology 69th Annual Scientific Meeting; 2005 Nov 12–17; San Diego, USA.Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–383. doi: 10.1002/acr.21558.16.Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–383. doi: 10.1002/acr.21558.16.Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–348.Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–348.Otten MH, Prince FH, Anink J, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis. 2013;72(5):721–727. doi: 10.1136/annrheumdis-2011-201060.Otten MH, Prince FH, Anink J, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis. 2013;72(5):721–727. doi: 10.1136/annrheumdis-2011-201060.Zavada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75(1):96–102. doi: 10.1136/annrheumdis-2014-205202.Zavada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75(1):96–102. doi: 10.1136/annrheumdis-2014-205202.Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF-receptor associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73(12):2160–2167. doi: 10.1136/annrheumdis-2013-204184.Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF-receptor associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73(12):2160–2167. doi: 10.1136/annrheumdis-2013-204184.Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759–2770. doi: 10.1002/art.39234.Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759–2770. doi: 10.1002/art.39234.Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24(5):599–605.Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24(5):599–605.

The authors declare that there are no conflicts of interest present.